Can Fite Biopharma Ltd (CANF) Rating Lowered to Strong Sell at ValuEngine
Can Fite Biopharma Ltd (NYSEMKT:CANF) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
Can Fite Biopharma (NYSEMKT CANF) traded down 1.14% on Thursday, hitting $1.73. 7,497 shares of the company traded hands. The stock’s 50-day moving average is $1.68 and its 200 day moving average is $1.81. The stock’s market cap is $26.82 million. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.82.
WARNING: “Can Fite Biopharma Ltd (CANF) Rating Lowered to Strong Sell at ValuEngine” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/09/can-fite-biopharma-ltd-canf-rating-lowered-to-strong-sell-at-valuengine.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.